Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
Clinical Trial Update: Moleculin Biotech has amended its Phase 3 clinical trial protocol for Annamycin in combination with Cytarabine, allowing for earlier unblinding of preliminary efficacy and safety data from the first 45 subjects, potentially accelerating the timeline for approval and strategic partnerships.
Trial Design and Expectations: The MIRACLE trial will include a global participant base and utilize an adaptive design to evaluate treatment efficacy, with initial results expected within 12 months, while the company continues to seek FDA approvals for Annamycin's use in treating relapsed or refractory acute myeloid leukemia.
Trade with 70% Backtested Accuracy
Analyst Views on MBRX
About MBRX
About the author
Moleculin Launches CEO Corner Platform for Investor Insights
- CEO Corner Launch: Moleculin Biotech announced the launch of its CEO Corner on February 13, 2026, designed to provide deeper insights into corporate developments and clinical progress from CEO Walter Klemp, thereby enhancing trust among investors and stakeholders.
- Clinical Trial Progress: The company is conducting the MIRACLE clinical trial to evaluate Annamycin in combination with cytarabine for treating relapsed acute myeloid leukemia (AML), paving the way for potential drug approval and demonstrating the company's commitment to advancing its pipeline.
- Drug Development Strategy: Annamycin, a next-generation oncology drug, aims to avoid multidrug resistance and reduce cardiotoxicity, expected to provide effective solutions for AML and soft tissue sarcoma, thereby enhancing the company's competitive position in cancer treatment.
- Enhanced Investor Engagement: The CEO Corner platform allows investors to submit questions and topics, facilitating direct communication with the company, reflecting Moleculin's emphasis on transparency and timely communication to enhance long-term shareholder value.
Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected
- Clinical Trial Progress: Moleculin expects to complete the unblinding of data for 45 subjects in the MIRACLE trial in Q1 2026, which is anticipated to provide critical efficacy data for treating acute myeloid leukemia (AML), thereby enhancing Annamycin's market recognition.
- New Indication Expansion: Annamycin is set to initiate a clinical trial for pancreatic cancer in 2026, funded by Atlantic Health, based on preclinical data showing unexpected activity in pancreatic cancer models, further enhancing its market potential.
- Global Trial Network: The MIRACLE trial has expanded to nine countries, including the US and several European nations, with 46 trial sites selected, and is expected to recruit the 90th subject by Q1 2026, demonstrating the company's strong execution capabilities on a global scale.
- Significant Market Opportunity: Annamycin is poised to become the world's first non-cardiotoxic anthracycline, and given that nearly half of cancer patients currently use cardiotoxic drugs, the market demand potential is enormous, likely attracting increased investor interest.
Moleculin Stock Falls 17% Despite Encouraging Phase 1 WP1066 Results for Pediatric Brain Tumors
Stock Performance: Moleculin Biotech, Inc. (MBRX) shares fell 16.84% to $3.90 despite reporting positive results from a Phase 1 clinical trial of WP1066 for children with recurrent malignant brain tumors.
Clinical Trial Results: The trial indicated that the treatment was safe, induced anti-tumor immune responses, and suppressed STAT3 activity, showing promising signs in a challenging pediatric cancer context.
Market Reaction: Following the announcement, the stock experienced significant volatility and a steep sell-off, with trading activity exceeding average levels as investors reassessed the company's near-term risks.
Trading Range: MBRX's stock trades within a 52-week range of approximately $3.63 to $91.25, highlighting its volatility in the biotech market.
Moleculin's WP1066 Demonstrates Immune Response and Positive Safety Profile in Pediatric Brain Cancer Study
Positive Clinical Trial Results: Moleculin Biotech's Phase 1 trial of WP1066 in children with recurrent malignant brain tumors showed anti-tumor immune activity and a favorable safety profile, with one patient achieving a partial tumor response.
Targeting Aggressive Cancers: The trial focused on aggressive pediatric brain cancers like diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), which have poor survival rates and limited treatment options.
Mechanism of Action: WP1066 is designed to inhibit oncogenic transcription factors and stimulate immune responses against tumors, addressing critical drivers of cancer cell survival and inflammation.
Future Research Plans: Following the promising results, a Phase 2 study is being planned to further evaluate the efficacy and long-term outcomes of WP1066 in pediatric patients.
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
- Enrollment Progress: Moleculin's MIRACLE trial has achieved 78% enrollment of its target subjects, up from 60% in November, with expectations to complete treatment of the first 45 subjects by Q1 2026, laying the groundwork for data unblinding.
- Clinical Activity Tracking: The company reports that blinded clinical activity is tracking within expected ranges, indicating strong enthusiasm from investigators in the US and Europe, particularly as recruitment challenges improve, reflecting a robust market demand for new therapies.
- Trial Design: The MIRACLE trial is a global multi-center, randomized, double-blind, placebo-controlled adaptive design, with plans for preliminary data unblinding at 45 subjects, which could provide strong support for Annamycin's approval if results are favorable.
- Future Outlook: Moleculin anticipates completing recruitment and treatment of 90 subjects in the first half of 2026, further advancing Annamycin's application in acute myeloid leukemia treatment and addressing a significant market gap.
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
- Enrollment Progress: Moleculin's MIRACLE trial enrollment has increased to 78%, up from 60% in November, with expectations to complete treatment of the first 45 subjects by Q1 2026, thereby laying the groundwork for data unblinding.
- Clinical Activity Tracking: The company reports that blinded clinical activity remains within expected ranges, indicating positive responses from investigators, particularly as recruitment improves in the US and Europe.
- Trial Design Advantages: The MIRACLE trial is a global, multi-center, randomized, double-blind, placebo-controlled adaptive design, with the first unblinding set to provide preliminary efficacy data for 45 subjects, potentially offering strong support for Annamycin's approval.
- Market Potential: Annamycin, as a next-generation anticancer drug, has received FDA Fast Track and Orphan Drug Designations, expected to fill a significant gap in acute myeloid leukemia treatment, presenting substantial market opportunities.
Moleculin Launches CEO Corner Platform for Investor Insights
- CEO Corner Launch: Moleculin Biotech announced the launch of its CEO Corner on February 13, 2026, designed to provide deeper insights into corporate developments and clinical progress from CEO Walter Klemp, thereby enhancing trust among investors and stakeholders.
- Clinical Trial Progress: The company is conducting the MIRACLE clinical trial to evaluate Annamycin in combination with cytarabine for treating relapsed acute myeloid leukemia (AML), paving the way for potential drug approval and demonstrating the company's commitment to advancing its pipeline.
- Drug Development Strategy: Annamycin, a next-generation oncology drug, aims to avoid multidrug resistance and reduce cardiotoxicity, expected to provide effective solutions for AML and soft tissue sarcoma, thereby enhancing the company's competitive position in cancer treatment.
- Enhanced Investor Engagement: The CEO Corner platform allows investors to submit questions and topics, facilitating direct communication with the company, reflecting Moleculin's emphasis on transparency and timely communication to enhance long-term shareholder value.
Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected
- Clinical Trial Progress: Moleculin expects to complete the unblinding of data for 45 subjects in the MIRACLE trial in Q1 2026, which is anticipated to provide critical efficacy data for treating acute myeloid leukemia (AML), thereby enhancing Annamycin's market recognition.
- New Indication Expansion: Annamycin is set to initiate a clinical trial for pancreatic cancer in 2026, funded by Atlantic Health, based on preclinical data showing unexpected activity in pancreatic cancer models, further enhancing its market potential.
- Global Trial Network: The MIRACLE trial has expanded to nine countries, including the US and several European nations, with 46 trial sites selected, and is expected to recruit the 90th subject by Q1 2026, demonstrating the company's strong execution capabilities on a global scale.
- Significant Market Opportunity: Annamycin is poised to become the world's first non-cardiotoxic anthracycline, and given that nearly half of cancer patients currently use cardiotoxic drugs, the market demand potential is enormous, likely attracting increased investor interest.
Moleculin Stock Falls 17% Despite Encouraging Phase 1 WP1066 Results for Pediatric Brain Tumors
Stock Performance: Moleculin Biotech, Inc. (MBRX) shares fell 16.84% to $3.90 despite reporting positive results from a Phase 1 clinical trial of WP1066 for children with recurrent malignant brain tumors.
Clinical Trial Results: The trial indicated that the treatment was safe, induced anti-tumor immune responses, and suppressed STAT3 activity, showing promising signs in a challenging pediatric cancer context.
Market Reaction: Following the announcement, the stock experienced significant volatility and a steep sell-off, with trading activity exceeding average levels as investors reassessed the company's near-term risks.
Trading Range: MBRX's stock trades within a 52-week range of approximately $3.63 to $91.25, highlighting its volatility in the biotech market.
Moleculin's WP1066 Demonstrates Immune Response and Positive Safety Profile in Pediatric Brain Cancer Study
Positive Clinical Trial Results: Moleculin Biotech's Phase 1 trial of WP1066 in children with recurrent malignant brain tumors showed anti-tumor immune activity and a favorable safety profile, with one patient achieving a partial tumor response.
Targeting Aggressive Cancers: The trial focused on aggressive pediatric brain cancers like diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), which have poor survival rates and limited treatment options.
Mechanism of Action: WP1066 is designed to inhibit oncogenic transcription factors and stimulate immune responses against tumors, addressing critical drivers of cancer cell survival and inflammation.
Future Research Plans: Following the promising results, a Phase 2 study is being planned to further evaluate the efficacy and long-term outcomes of WP1066 in pediatric patients.
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
- Enrollment Progress: Moleculin's MIRACLE trial has achieved 78% enrollment of its target subjects, up from 60% in November, with expectations to complete treatment of the first 45 subjects by Q1 2026, laying the groundwork for data unblinding.
- Clinical Activity Tracking: The company reports that blinded clinical activity is tracking within expected ranges, indicating strong enthusiasm from investigators in the US and Europe, particularly as recruitment challenges improve, reflecting a robust market demand for new therapies.
- Trial Design: The MIRACLE trial is a global multi-center, randomized, double-blind, placebo-controlled adaptive design, with plans for preliminary data unblinding at 45 subjects, which could provide strong support for Annamycin's approval if results are favorable.
- Future Outlook: Moleculin anticipates completing recruitment and treatment of 90 subjects in the first half of 2026, further advancing Annamycin's application in acute myeloid leukemia treatment and addressing a significant market gap.
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
- Enrollment Progress: Moleculin's MIRACLE trial enrollment has increased to 78%, up from 60% in November, with expectations to complete treatment of the first 45 subjects by Q1 2026, thereby laying the groundwork for data unblinding.
- Clinical Activity Tracking: The company reports that blinded clinical activity remains within expected ranges, indicating positive responses from investigators, particularly as recruitment improves in the US and Europe.
- Trial Design Advantages: The MIRACLE trial is a global, multi-center, randomized, double-blind, placebo-controlled adaptive design, with the first unblinding set to provide preliminary efficacy data for 45 subjects, potentially offering strong support for Annamycin's approval.
- Market Potential: Annamycin, as a next-generation anticancer drug, has received FDA Fast Track and Orphan Drug Designations, expected to fill a significant gap in acute myeloid leukemia treatment, presenting substantial market opportunities.
